Pulmovant
Pulmovant is seeking a Manager or Senior Manager of Statistical Programming to lead programming activities for clinical studies and regulatory submissions within its pulmonary/respiratory portfolio. This role involves developing and validating SAS and R programs to produce CDISC-compliant datasets and deliverables while ensuring alignment with FDA/EMA regulatory guidelines. The position requires collaboration with cross-functional teams to manage programming timelines, oversee vendor deliverables, and mentor junior programmers.
Pulmovant is a clinical-stage biopharmaceutical company singularly focused on developing innovative inhaled therapies for pulmonary diseases, including pulmonary hypertension. The company's lead candidate, mosliciguat, is a potentially first-in-class once-daily inhaled treatment with a differentiated soluble guanylate cyclase (sGC) activation mechanism. Pulmovant is advancing mosliciguat through clinical trials with the goal of transforming the treatment paradigm for patients with pulmonary diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Pulmovant.
Pulmovant didn’t post a salary, so this is our estimate from similar listings.
Pulmovant completes enrollment for PH-ILD treatment trial
1 month ago